Tourette Syndrome - Pipeline Review, H2 2017 - Product Image

Tourette Syndrome - Pipeline Review, H2 2017

  • ID: 4330517
  • Report
  • Region: Global
  • 75 Pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • Synchroneuron Inc
  • Therapix Biosciences Ltd
  • MORE
Tourette Syndrome - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H2 2017, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 6, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • Synchroneuron Inc
  • Therapix Biosciences Ltd
  • MORE
Introduction

Tourette Syndrome - Overview

Tourette Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tourette Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tourette Syndrome - Companies Involved in Therapeutics Development

Abide Therapeutics Inc

Catalyst Pharmaceuticals Inc

Neurocrine Biosciences Inc

Psyadon Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Synchroneuron Inc

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Tourette Syndrome - Drug Profiles

(amfetamine + guanfacine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1431 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acamprosate calcium SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPP-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

deutetrabenazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol + palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ecopipam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valbenazine tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vigabatrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tourette Syndrome - Dormant Projects

Tourette Syndrome - Discontinued Products

Tourette Syndrome - Product Development Milestones

Featured News & Press Releases

May 23, 2017: Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA For Treatment of Tourette Syndrome

May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome

Apr 18, 2017: Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America

Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children

Jan 17, 2017: Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (valbenazine) in Adults with Tourette Syndrome

Jan 04, 2017: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourette's Syndrome Using Cannabinoid-based Drug

Aug 31, 2016: Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA for VMAT2 Inhibitor Valbenazine

Jul 28, 2016: Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome

Jun 15, 2016: Therapix Biosciences Filed an Application with the FDA to Approve an Orphan Designation for the Drug Developed Based on the Entourage Technology for Treating Tourette Syndrome

Feb 03, 2016: Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette’s Syndrome in Children

Feb 02, 2016: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome

Dec 16, 2015: Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome

Oct 20, 2015: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome

Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population

Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Tourette Syndrome, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Tourette Syndrome - Pipeline by Abide Therapeutics Inc, H2

Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H2

Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc, H2

Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals Inc, H2

Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc, H2

Tourette Syndrome - Pipeline by Synchroneuron Inc, H2

Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2

Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H2

Tourette Syndrome - Dormant Projects, H2

Tourette Syndrome - Discontinued Products, H2

List of Figures:

Number of Products under Development for Tourette Syndrome, H2

Number of Products under Development by Companies, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Top 10 Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abide Therapeutics Inc
  • Catalyst Pharmaceuticals Inc
  • Neurocrine Biosciences Inc
  • Psyadon Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • Synchroneuron Inc
  • Teva Pharmaceutical Industries Ltd
  • Therapix Biosciences Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll